Pharma v Biotech: New Rules?
Pharma is under pressure. Fast-adapting biotech may have answers
The global market for obesity therapeutics has undergone a seismic shift, catalyzed by the rise of GLP-1-based therapies which in turn has driven a surge in strategic dealmaking.
Introduction
US price curbs force cuts, narrow options
Pharma goes direct-to-patient
Outsourced R&D shapes biotech investment
In a buyer’s market, pharma carves out assets and contingencies
More funding options for (some) biotechs
Modular biopharma
How Evaluate Helps